-
1.
公开(公告)号:US20250009849A1
公开(公告)日:2025-01-09
申请号:US18891899
申请日:2024-09-20
Applicant: Horizon Therapeutics USA, Inc.
Inventor: Jeffrey D. KENT , Brian LAMOREAUX
Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.
-
2.
公开(公告)号:US20240415814A1
公开(公告)日:2024-12-19
申请号:US18818183
申请日:2024-08-28
Applicant: LG CHEM, LTD.
Inventor: Jieun LEE , Heemin GWAK , Seong Hye SHIN , Ji Young MIN , Min Hee KIM , Junyu KIM , Jung Youn SEO , June Sik MUNE
IPC: A61K31/4155 , A61K31/165 , A61K31/192 , A61K31/195 , A61K31/4152 , A61P19/06
Abstract: The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or inhibiting a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the serum uric acid concentration in a patient with a hyperuricemia-related disease.
-
公开(公告)号:US20240382423A1
公开(公告)日:2024-11-21
申请号:US17921356
申请日:2021-09-22
Applicant: HANGZHOU MEIYI BIOTECHNOLOGY CO., LTD.
Inventor: Boke Zhang
Abstract: An external nano liniment for gout and a preparation method thereof are provided. The external nano liniment for gout includes a cream phase and nanoparticles dispersed in the cream phase, wherein the nanoparticles are a coating structure having a water phase, an oil phase and a water phase in sequence from inside to outside, an active ingredient used for treating gout is embedded or dispersed in the water phase and/or the oil phase of the nanoparticles, and a size distribution of the nanoparticles is in a range of 1-200 nm.
-
公开(公告)号:US12121566B2
公开(公告)日:2024-10-22
申请号:US16777625
申请日:2020-01-30
Applicant: Horizon Therapeutics USA, Inc.
Inventor: Jeffrey D. Kent , Brian Lamoreaux
CPC classification number: A61K38/44 , A61K9/0053 , A61K31/52 , A61P19/06
Abstract: The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.
-
公开(公告)号:US20240307412A1
公开(公告)日:2024-09-19
申请号:US18670600
申请日:2024-05-21
Applicant: Dyve Biosciences, Inc.
Inventor: Ryan Beal
IPC: A61K31/573 , A61K9/00 , A61K45/06 , A61K47/10 , A61P19/06
CPC classification number: A61K31/573 , A61K9/0014 , A61K9/0053 , A61K45/06 , A61K47/10 , A61P19/06
Abstract: The present disclosure relates to transdermal formulations, compositions, and methods for treating or preventing inflammation or a symptom thereof, e.g., inflammatory pain.
-
公开(公告)号:US20240262808A1
公开(公告)日:2024-08-08
申请号:US18557919
申请日:2022-04-28
Inventor: Dongfang SHI , Changjin FU , Yan YANG
IPC: C07D403/04 , A61K31/416 , A61K31/4192 , A61K31/4439 , A61P19/06 , C07D231/56 , C07D401/04 , C07D405/14 , C07D409/04
CPC classification number: C07D403/04 , A61K31/416 , A61K31/4192 , A61K31/4439 , A61P19/06 , C07D231/56 , C07D401/04 , C07D405/14 , C07D409/04
Abstract: It discloses a compound shown in general formula (1) or a pharmaceutically acceptable salt thereof and a method for preparation of the compound; the compound is a xanthine oxidase inhibitor with xanthine oxidase inhibiting activity; the compound has an excellent xanthine oxidase inhibitory activity and has potential application value in anti-gout drugs, anti-hyperuricemia drugs, etc.
-
公开(公告)号:US20240124409A1
公开(公告)日:2024-04-18
申请号:US18519062
申请日:2023-11-26
Applicant: NANJING UNIVERSITY OF CHINESE MEDICINE
IPC: C07D307/93 , A61P1/16 , A61P11/00 , A61P13/12 , A61P19/02 , A61P19/06 , A61P29/00 , A61P31/00 , A61P35/00
CPC classification number: C07D307/93 , A61P1/16 , A61P11/00 , A61P13/12 , A61P19/02 , A61P19/06 , A61P29/00 , A61P31/00 , A61P35/00
Abstract: The present application discloses a class of guaianolide sesquiterpene lactone derivatives and pharmaceutical use thereof. The guaianolide sesquiterpene lactone derivative or a pharmaceutically acceptable salt thereof is shown as general formula I. In the present application, a class of novel guaianolide sesquiterpene lactone derivatives are found by structural optimization with abundant natural ingredients such as parthenolide and dehydrocostus lactone as raw materials, which derivatives have good inhibitory activity on the activation of the NLRP3 inflammasome, and the chemical stability, water solubility and oral bioavailability of which are significantly improved, and it is verified by experiments that the derivatives have inhibitory effects on the activity of the NLRP3 inflammasome and have potential pharmaceutical applications.
-
公开(公告)号:US20240024385A1
公开(公告)日:2024-01-25
申请号:US17814459
申请日:2022-07-22
Applicant: Ningbo Beiyijia Biotechnology Co., Ltd.
Inventor: Haifeng LIU , Chunyan LI , Yanhong LIU , Yashan CHEN , Fengtao ZHU , Hong LIU , Tingting PI , Qingshan LI
IPC: A61K35/747 , A61K47/36 , A61K31/519 , A61K31/426 , A61K31/343 , A61K31/192 , A61P19/06
CPC classification number: A61K35/747 , A61K47/36 , A61K31/519 , A61K31/426 , A61K31/343 , A61K31/192 , A61P19/06
Abstract: Probiotics for the purine-degrading capability under the condition of a rich-nutrient medium are screened, and a culture environment relatively simulating the human intestinal tract is obtained, so that Lactobacillus reuteri strains KLR-1, KLR-3, KLR-4 and KLR-13 are obtained. The probiotic strain or the composition containing the strain has a significant serum uric acid-reducing effect in an animal model. The composition has a probiotic-containing composition and prebiotics. The probiotic-containing composition is one or more of Lactobacillus reuteri, Lactobacillus ferrnenturn, Bacillus coagulans, Lactobacillus rhamnosus, Lactobacillus casei and Lactobacillus plantarum. The prepared compound probiotic powder can significantly reduce the serum uric acid of gout patients and has the effect of dissolving urate crystals.
-
9.
公开(公告)号:US20230346765A1
公开(公告)日:2023-11-02
申请号:US17905995
申请日:2021-03-03
Applicant: Baylor College of Medicine
Inventor: Changyi Chen , Qizhi Yao , Jian-Ming Lu
IPC: A61K31/455 , A61K31/5377 , A61K31/519 , A61K31/11 , A61P19/06
CPC classification number: A61K31/455 , A61K31/5377 , A61K31/519 , A61K31/11 , A61P19/06
Abstract: Provided herein are methods of using niflumic acid and derivatives thereof for treating a disease or condition associated with elevated serum uric levels in a subject. The methods include administering to the subject an effective amount of a pharmaceutical composition as described herein. The disease or condition associated with elevated serum uric levels can include, for example, gout, hyperuricemia, or cardiovascular disease. Also provided herein are methods of reducing serum uric acid levels in a subject and methods for inhibiting xanthine oxidase activity in a cell. Novel pharmaceutical compositions are also provided herein. (I)
-
公开(公告)号:US11802121B2
公开(公告)日:2023-10-31
申请号:US18049052
申请日:2022-10-24
Applicant: Pfizer Inc.
Inventor: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , Matthew S. Dowling , David Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Gajendra Ingle , Wenhua Jiao , Chris Limberakis , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC: A61K31/496 , A61K31/4545 , C07D401/14 , C07D487/04 , A61P3/00 , A61P15/10 , A61P17/06 , A61P9/10 , A61P19/06 , A61P25/28 , A61P25/30 , A61P43/00 , A61P1/16 , A61P25/02 , A61P3/04 , A61P19/02 , A61P3/10 , A61P13/12 , A61P25/18 , A61P1/00 , A61P15/00 , A61P25/16 , C07D405/14 , C07D413/14 , C07D471/04
CPC classification number: C07D401/14 , A61K31/4545 , A61K31/496 , A61P1/00 , A61P1/16 , A61P3/00 , A61P3/04 , A61P3/10 , A61P9/10 , A61P13/12 , A61P15/00 , A61P15/10 , A61P17/06 , A61P19/02 , A61P19/06 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/28 , A61P25/30 , A61P43/00 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
-
-
-
-
-
-
-
-